|
Neuroimaging placeholder
|
| Also Known As |
Primary Angiitis of the CNS, PACNS, Cerebral Vasculitis |
| ICD-10 |
I67.7 |
| Classification |
Primary (PACNS) and Secondary CNS vasculitis |
| Incidence |
2.4-4.6 per million person-years |
| Peak Age |
40-60 years |
| Gender Ratio |
Slight male predominance (1.5:1) |
| Key Features |
Headache, stroke, cognitive decline, seizures |
| Pathology |
Granulomatous inflammation of vessel walls |
Cns Vasculitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Central Nervous System Vasculitis (CNS Vasculitis), also known as Primary Angiitis of the Central Nervous System (PACNS), is a rare but serious inflammatory disorder characterized by targeted inflammation of the blood vessels within the brain and spinal cord. This condition represents a distinct form of vasculitis that affects exclusively the central nervous system, distinguishing it from systemic vasculitides that involve multiple organ systems 1.
CNS vasculitis results from immune-mediated inflammation of the arterial and venous walls, leading to vessel wall thickening, luminal narrowing, and subsequent ischemia. The inflammatory process can cause stroke, transient ischemic attacks, cognitive decline, seizures, and other neurological manifestations. Without timely diagnosis and treatment, CNS vasculitis can lead to permanent neurological disability or death 2.
The relationship between CNS vasculitis and neurodegenerative diseases has become an area of increasing research interest. Vascular contributions to Alzheimer's Disease (AD), Vascular Dementia, and other neurodegenerative conditions have highlighted the importance of understanding cerebrovascular pathology in neurodegeneration 3.
CNS vasculitis is a rare condition with the following epidemiological characteristics:
- Incidence: Approximately 2.4-4.6 cases per million person-years 4.
- Prevalence: Estimated at 1-2 per 100,000 individuals.
- Age distribution: Can occur at any age, but peak incidence is in the 40-60 year age group.
- Gender: Slight male predominance (approximately 1.5:1 male-to-female ratio).
- Geographic variation: Cases have been reported worldwide with no clear ethnic predilection.
Primary Angiitis of the CNS is confined to the brain and spinal cord without systemic involvement:
- Granulomatous angiitis: The most common form, characterized by granulomatous inflammation with multinucleated giant cells
- Lymphocytic vasculitis: T-lymphocyte predominant inflammation
- [Amyloid angiitis-related vasculitis]: Associated with cerebral amyloid angiopathy (CAA)
CNS involvement as part of systemic vasculitis or other conditions:
- Systemic vasculitides: Giant cell arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis
- Infection-associated: Syphilis, tuberculosis, varicella zoster, HIV, hepatitis viruses
- Autoimmune diseases: Systemic lupus erythematosus, antiphospholipid syndrome, Behçet's disease
- Malignancy-associated: Lymphoma, leukemia, primary CNS lymphoma
- Drug-induced: Certain medications and illicit drugs
The pathogenesis of CNS vasculitis involves multiple immune mechanisms 5:
- T-cell mediated immunity: CD4+ and CD8+ T-lymphocytes infiltrate vessel walls, releasing pro-inflammatory cytokines
- Humoral immunity: B-cell activation and autoantibody production in some forms
- Macrophage involvement: Macrophages and multinucleated giant cells in granulomatous forms
- Endothelial activation: Up-regulation of adhesion molecules and chemokines
The inflammatory process produces characteristic pathological changes 6:
- Intimal hyperplasia: Proliferation of smooth muscle cells and fibroblasts in the vessel intima
- Medial destruction: Degradation of the muscular layer of vessel walls
- Adventitial inflammation: Perivascular inflammatory cell infiltrates
- Lumen narrowing: Progressive narrowing leads to decreased blood flow and ischemia
- Wall necrosis: Fibrinoid necrosis in severe cases
- Aneurysm formation: Weakened vessel walls may form aneurysms
CNS vasculitis disrupts the Blood-Brain Barrier (BBB), allowing immune cell infiltration and contributing to neuroinflammation 7:
- BBB breakdown: Inflammatory mediators increase vascular permeability
- Perivascular edema: Fluid accumulation around affected vessels
- Immune cell entry: Autoreactive T-cells and antibodies access CNS tissue
The presentation of CNS vasculitis is highly variable 1:
- Headache: Present in 50-70% of patients, often severe and progressive
- Cognitive impairment: Memory deficits, executive dysfunction, and dementia-like presentations
- Stroke and TIA: Ischemic or hemorrhagic events, often in multiple territories
- Seizures: Focal or generalized seizures in 25-35% of patients
- Fever: Present in approximately 30% of cases
- Constitutional symptoms: Fatigue, weight loss, night sweats
- Cranial neuropathies: Visual disturbances, facial weakness, hearing loss
- Movement disorders: Tremor, parkinsonism, chorea
- Spinal cord involvement: Myelopathy, transverse myelitis
- Psychiatric symptoms: Depression, psychosis, personality changes
- Acute presentation: Stroke-like onset with focal deficits
- Subacute progressive: Insidious cognitive decline over weeks to months
- Relapsing-remitting: Multiple discrete events with partial recovery
- Mass lesion: Headache with focal deficits and enhancing lesion on imaging
CNS vasculitis represents a model for understanding how vascular pathology contributes to neurodegeneration 3:
The relationship between CAA and CNS vasculitis is particularly relevant 8:
- CAA-related inflammation: A distinct entity where inflammation surrounds amyloid-laden vessels
- Shared risk factors: Both conditions increase with age and apolipoprotein E ε4 allele
- Treatment implications: CAA-related inflammation often responds dramatically to immunosuppression
¶ Stroke and Dementia
CNS vasculitis is a cause of vascular cognitive impairment and Vascular Dementia 9:
- Multi-infarct state: Multiple small vessel infarcts accumulate, leading to Vascular Dementia
- Strategic infarcts: Damage to critical brain regions (thalamus, hippocampus) disproportionately affects cognition
- White matter disease: Ischemic leukoaraiosis contributes to executive dysfunction
- Inflammatory markers: Elevated ESR and CRP in active disease
- Autoantibody screening: ANA, ANCA, antiphospholipid antibodies
- CSF analysis: Elevated protein, pleocytosis, occasionally oligoclonal bands
- Infection workup: HIV, syphilis, hepatitis serologies
MRI is the imaging modality of choice 10:
- MR angiography: Shows vessel wall thickening and luminal narrowing
- Vessel wall imaging: High-resolution MRI can demonstrate vessel wall enhancement
- Parenchymal findings: T2 hyperintensities, infarcts, hemorrhages, enhancement patterns
- Diffusion-weighted imaging: Acute infarcts appear as restricted diffusion
Conventional angiography remains important:
- Findings: Segmental narrowing ("beading"), aneurysms, occlusions
- Sensitivity: 60-80% for medium-to-large vessel involvement
- Limitations: Less sensitive for small vessel disease
Brain or leptomeningeal biopsy provides definitive diagnosis:
- Target sites: Enhancing lesions, leptomeninges
- Histopathology: Granulomatous inflammation, lymphocytic infiltration, necrotizing vasculitis
- Yield: Approximately 75% diagnostic yield with appropriate targeting
High-dose corticosteroids remain first-line treatment 11:
- Methylprednisolone: 1 gram IV daily for 3-5 days
- Prednisone: 1 mg/kg/day oral with taper over 6-12 months
- Cyclophosphamide: Often used for severe disease (IV or oral)
- Rituximab: Anti-CD20 monoclonal antibody, particularly for ANCA-associated forms
- Azathioprine: For maintenance therapy
- Mycophenolate mofetil: Alternative maintenance agent
- Tocilizumab: IL-6 receptor antagonist in refractory cases
- Abatacept: CTLA4-Ig for select patients
Low-dose aspirin may provide benefit:
- Reduces thrombotic complications
- May have anti-inflammatory effects
¶ Monitoring and Prognosis
- Serial imaging: Monitor treatment response
- Relapse risk: Approximately 25-30% relapse rate
- Outcomes: Early treatment improves outcomes; residual deficits common
The study of Cns Vasculitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Primary angiitis of the central nervous system — Neurology (2024)
- CNS vasculitis: Pathogenesis and clinical features — Nature Reviews Neurology (2023)
- Vascular contributions to neurodegeneration — The Lancet Neurology (2023)
- Epidemiology of primary CNS vasculitis — Neurology (2022)
- Immunopathogenesis of CNS vasculitis — Journal of neuroinflammation (2024)
- Pathology of cerebral vasculitis — Brain Pathology (2023)
- Blood-Brain Barrier in CNS vasculitis — Annals of Neurology (2023)
- Cerebral amyloid angiopathy-related vasculitis — Neurology (2024)
- Vascular cognitive impairment and dementia — Nature Reviews Disease Primers (2024)
- Neuroimaging of CNS vasculitis — Radiology (2023)
- Treatment of primary CNS vasculitis — Arthritis & Rheumatology (2024)
- Relapse in CNS vasculitis — Neurology: Neuroimmunology & neuroinflammation (2023)
- Prognosis of CNS vasculitis — Stroke (2024)
- High-resolution vessel wall MRI — Journal of Neurology, Neurosurgery & Psychiatry (2024)
- Biologic therapies in refractory CNS vasculitis — Rheumatology (2024)